- Published at
- by investing.com
positive
positive
GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings By Investing.com
GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings
News for GeNeuro SA (GNRO.PA)
- Published at
- by globenewswire.com
positivepositiveS1PR Modulators Market to Register Immense Growth During the Study Period (2020–2034) | DelveInsight
The S1PR modulators market is expected to show a remarkable expansion, driven by advancements in pharmaceutical research and therapeutic applications. With...- Published at
- by prnewswire.com
mixedmixedCough-assisted Devices Global Market to Register Incremental Growth at a CAGR of ~7% by 2028 | DelveInsight
/PRNewswire/ -- DelveInsight's Cough-assisted Devices Market Insights report provides the current and forecast market analysis, individual leading...- Published at
- by prnewswire.com
mixedmixedMonoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and...- Published at
- by marketscreener.com
neutralneutralGeNeuro : 2022 Universal Registration Document
A Swiss joint stock company with share capital of 1,249,951.40 Swiss francs Registered and principal office: 3 chemin du Pr?leuri - 1228 Plan-les-Ouates... | April 30, 2023- Published at
- by globenewswire.com
negativenegativeRelapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
RRMS is the most common subtype (approximately 87%), which is characterized by unpredictable acute attacks followed by periods of remission. The growing...- Published at
- by globenewswire.com
mixedmixedMultiple Sclerosis Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight
As per DelveInsight Multiple Sclerosis pipeline involves 100+ key companies developing 100+ Multiple Sclerosis treatment therapies...